Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE BioHealth Innovation, Inc.
- Representatives from Sigma-Tau Pharmaceuticals Inc., Alexandria Real Estate Equities, Inc., and Deloitte Consulting LLP Take New Board Seats -
- Charles Morton Becomes New Venable LLP Representative on Board while Mike Baader Stays on as Board Member (Now as Greenspring Associates Representative) -
ROCKVILLE, Md. and BALTIMORE, Aug. 12, 2014 /PRNewswire/ -- BioHealth Innovation, Inc. (BHI) announced today the appointment of four new members to its Board of Directors. Dave Lemus, Chief Executive Officer, Sigma-Tau Pharmaceuticals Inc.; Joel S. Marcus, Chairman, Chief Executive Officer, and Founder, Alexandria Real Estate Equities, Inc. (Alexandria Venture Investments); and Beth Meagher, Principal, Deloitte Consulting LLP, have joined the BHI Board of Directors, effective August 7, 2014, based upon their organizations' newly committed support of BHI. Charles "Chuck" Morton now represents Venable LLP on the Board, as another new Board member, while Mike Baader, formerly with Venable, will continue to hold a seat on the Board, but now as a representative of Greenspring Associates. Cynthia L. Collins, CEO, Clarient, who had served on the BHI Board since early 2013, is stepping down from her Board position after relocating to the West Coast.
"The expansion of and continued diversity within the BHI Board, based upon new key industry and service provider representatives who are all deeply involved in life sciences, is a testament to the positive impact BHI has made on the Central Maryland biohealth community to date," said Richard Bendis, BHI President & CEO.
"We look forward to the contributions from the new Board members representing these organizations. We're also pleased to welcome a new Venable representative to the Board and that Mike Baader will continue to add value to the organization now that he is on the Greenspring Associates team," said Douglas Liu, Chair, BHI Board of Directors, and Senior Vice President of Global Operations for Qiagen. "And, on behalf of the BHI staff and Board, I would also like to offer gratitude to Cynthia Collins for her service and contributions to the BHI Board over the last year and half."
About BHI's New Board Members
Dave Lemus leads Sigma-Tau Pharmaceuticals' activities in North America from the company's headquarters in Gaithersburg, where R&D, global manufacturing and sales/commercialization within the Americas occurs. Sigma-Tau is dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Mr. Lemus also currently serves as a non-executive Board member of various European and North American companies, including Board chair of Proteros GmbH, a leading structural biology focused company co-founded by Nobel prize-winner Dr. Robert Huber. Additionally he serves as a non-executive Board member of Medigene AG, a publicly listed biotechnology company in Germany, as well as Axela Inc., a private diagnostics company based in Toronto, Canada.
Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (Alexandria Venture Investments), the largest and leading REIT uniquely focused on collaborative science and technology campuses in urban innovation clusters. He co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million of seed capital, and has led its growth into a publicly traded, investment-grade REIT with a total market capitalization of approximately $9 billion and dominant market presence in leading AAA locations, including Greater Boston, the San Francisco Bay Area, New York City, Seattle, San Diego, Maryland, and Research Triangle Park. Mr. Marcus also founded the renowned Alexandria Summit, an invitation-only gathering of the world's foremost visionaries from the biopharmaceutical, medical, academic, financial, philanthropic, advocacy, and government communities, to address the most critical global healthcare challenges.
Beth Meagher has over 19 years of experience leading strategic initiatives for clients in commercial, government, and non-profit sectors. Currently, she is leading Deloitte's Federal Strategy Practice with over 90 consultants and she started and leads Deloitte's Translational Science Team with over 35 practitioners. Ms. Meagher is an expert at go-to market strategy development, routinely fostering high performing teams that outperform the market. She has C-suite relationships across the federal, commercial, and non-profit markets.
Chuck Morton consistently ranks among the top M&A lawyers in the country. He co-chairs Venable's Corporate Practice Group, splitting his time between Venable's Washington and Baltimore offices. In his national practice, he helps entrepreneurs, investors and lenders solve complex problems as they create, build, and buy or sell businesses. He routinely advises on mergers and acquisitions and financings, including every flavor of equity investment. He regularly acts on behalf of private equity groups and banks.
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
©2012 PR Newswire. All Rights Reserved.